Literature DB >> 25316298

Secoisolariciresinol diglucoside in high-fat diet and streptozotocin-induced diabetic nephropathy in rats: a possible renoprotective effect.

Iman O Sherif1.   

Abstract

Due to substantial morbidity and high complication rate of diabetes mellitus, which is considered as the third killer in the world, a search for the effective blockade of the progression of diabetic nephropathy (DN) remains a therapeutic challenge. Alternative antidiabetic drugs from natural plants are highly demanded nowadays. The aim of this study was to investigate the renoprotective effect of secoisolariciresinol diglucoside (SDG) on DN induced in rats. Diabetes was induced in male Sprague-Dawley rats by a high-fat diet (HFD) and an intraperitoneal 35 mg/kg streptozotocin (STZ) injection. Rats were divided into four groups: normal control rats, diabetic control rats, diabetic rats treated with SDG at 10 mg/kg/day for 4 weeks, and diabetic rats treated with SDG at 20 mg/kg/day for 4 weeks. At the end of the treatment, blood and renal tissue samples were collected for biochemical examination. The results revealed that SDG treatment significantly increased insulin level and decreased blood glucose, fructosamine, creatinine, and blood urea nitrogen levels in diabetic rats. Also, SDG significantly increased renal reduced glutathione, superoxide dismutase and decreased malondialdehyde and nitric oxide levels. In addition, SDG downregulated the renal nuclear factor kappa-B (NF-κB), tumor necrosis factor (TNF)-α, and inducible nitric oxide synthase (iNOS) and upregulated renal survivin and B-cell lymphoma-2 (Bcl-2) expressions when compared with untreated diabetic control rats. This study demonstrated, for the first time, the renoprotective effects of SDG in HFD/STZ-induced DN in rats through correction of hyperglycemia; attenuation of oxidative/nitrosative stress markers; downregulation of renal expressions of inflammatory markers NF-κB, TNF-α, and iNOS; along with upregulation of renal expressions of antiapoptotic markers survivin and Bcl-2.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25316298     DOI: 10.1007/s13105-014-0364-x

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   4.158


  43 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocin-treated diabetic rats.

Authors:  Yong Wu; Jing Ping Ouyang; Ke Wu; Shi Shun Wang; Chong Yuan Wen; Zheng Yuan Xia
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

3.  Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats.

Authors:  Sameer Sharma; Shrinivas K Kulkarni; Kanwaljit Chopra
Journal:  Clin Exp Pharmacol Physiol       Date:  2006-10       Impact factor: 2.557

Review 4.  Diabetes, oxidative stress, and antioxidants: a review.

Authors:  A C Maritim; R A Sanders; J B Watkins
Journal:  J Biochem Mol Toxicol       Date:  2003       Impact factor: 3.642

Review 5.  Health effects with consumption of the flax lignan secoisolariciresinol diglucoside.

Authors:  Jennifer L Adolphe; Susan J Whiting; Bernhard H J Juurlink; Lilian U Thorpe; Jane Alcorn
Journal:  Br J Nutr       Date:  2009-12-15       Impact factor: 3.718

Review 6.  Potentiation of cellular antioxidant capacity by Bcl-2: implications for its antiapoptotic function.

Authors:  Jung-Hee Jang; Young-Joon Surh
Journal:  Biochem Pharmacol       Date:  2003-10-15       Impact factor: 5.858

Review 7.  Diabetic nephropathy and antioxidants.

Authors:  Majid Tavafi
Journal:  J Nephropathol       Date:  2013-01-01

8.  Intravenous renal cell transplantation with SAA1-positive cells prevents the progression of chronic renal failure in rats with ischemic-diabetic nephropathy.

Authors:  Katherine J Kelly; Jizhong Zhang; Ling Han; Mingsheng Wang; Shaobo Zhang; Jesus H Dominguez
Journal:  Am J Physiol Renal Physiol       Date:  2013-10-16

9.  Renoprotective effects of olmesartan medoxomil on diabetic nephropathy in streptozotocin-induced diabetes in rats.

Authors:  Xiaofei Si; Peng Li; Yan Zhang; Yan Zhang; Wei Lv; Dong Qi
Journal:  Biomed Rep       Date:  2013-10-09

10.  Flaxseed lignan complex administration in older human type 2 diabetics manages central obesity and prothrombosis-an invitation to further investigation into polypharmacy reduction.

Authors:  D E Barre; K A Mizier-Barre; E Stelmach; J Hobson; O Griscti; A Rudiuk; D Muthuthevar
Journal:  J Nutr Metab       Date:  2012-10-04
View more
  5 in total

1.  Inducible nitric oxide synthase-derived nitric oxide reduces vagal satiety signalling in obese mice.

Authors:  Yang Yu; Sung Jin Park; Michael J Beyak
Journal:  J Physiol       Date:  2018-12-18       Impact factor: 5.182

Review 2.  Distribution, biosynthesis and therapeutic potential of lignans.

Authors:  Navdeep Singh Plaha; Sumegha Awasthi; Ayushi Sharma; Nutan Kaushik
Journal:  3 Biotech       Date:  2022-09-02       Impact factor: 2.893

3.  Combined systems pharmacology and fecal metabonomics to study the biomarkers and therapeutic mechanism of type 2 diabetic nephropathy treated with Astragalus and Leech.

Authors:  Ruiqun Chen; Chengbin Liao; Qian Guo; Lirong Wu; Lei Zhang; Xiufeng Wang
Journal:  RSC Adv       Date:  2018-08-01       Impact factor: 4.036

Review 4.  Mechanisms of Herbal Nephroprotection in diabetes mellitus.

Authors:  Dorin Dragoș; Maria Mirabela Manea; Delia Timofte; Dorin Ionescu
Journal:  J Diabetes Res       Date:  2020-06-30       Impact factor: 4.011

5.  Atherosclerosis Development and Aortic Contractility in Hypercholesterolemic Rabbits Supplemented with Two Different Flaxseed Varieties.

Authors:  Jolanta Bujok; Dorota Miśta; Edyta Wincewicz; Bożena Króliczewska; Stanisław Dzimira; Magdalena Żuk
Journal:  Foods       Date:  2021-03-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.